Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment

BACKGROUND: Osimertinib yields significant tumor responses and durations of progression‐free survival (PFS) in patients with acquired T790M mutations. However, the evidence supporting liquid biopsy‐guided treatment is still limited. This study examined the real‐world benefits of osimertinib in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Po‐Lan, Yang, Szu‐Chun, Chen, Yi‐Lin, Wu, Yi‐Lin, Lin, Chia‐Ying, Chang, Wei‐Yuan, Tseng, Yau‐Lin, Lai, Wu‐Wei, Ho, Chung‐Liang, Lin, Chien‐Chung, Su, Wu‐Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792511/
https://www.ncbi.nlm.nih.gov/pubmed/31433117
http://dx.doi.org/10.1002/cam4.2485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792511/
https://www.ncbi.nlm.nih.gov/pubmed/31433117
http://dx.doi.org/10.1002/cam4.2485

Ejemplares similares